Cosmo Pharmaceuticals N.V./Fr. COPN
1D1W1MYTD1Y5YMAX
About Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company based in Lainate, Italy, focusing on the development and manufacturing of products for specific gastrointestinal diseases. The company's core business involves oral therapies, particularly for conditions such as inflammatory bowel disease and colon cancer. Notable products include Lialda/Mezavant, a treatment for ulcerative colitis, and Eleview, a medical device used in endoscopic procedures. Cosmo Pharmaceuticals leverages proprietary drug delivery technologies to enhance treatment efficacy and patient compliance. While headquartered in Italy, it operates primarily within the European market and maintains a strategic partnership network to expand its global reach.
- Ticker
- Fr. COPN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 365
- Headquarters
- Dublin, Ireland
COPN Metrics
BasicAdvanced
CHF 954M
-
-CHF 0.36
1.48
CHF 1.92
3.32%
Price and volume
Market cap
CHF 954M
Beta
1.48
52-week high
CHF 129.40
52-week low
CHF 55.50
Average daily volume
31K
Dividend rate
CHF 1.92
Financial strength
Current ratio
10.662
Quick ratio
9.836
Long term debt to equity
0.627
Total debt to equity
0.754
Interest coverage (TTM)
-65.87%
Profitability
EBITDA (TTM)
1.131
Gross margin (TTM)
45.51%
Net profit margin (TTM)
-6.19%
Operating margin (TTM)
-10.84%
Effective tax rate (TTM)
-53.39%
Revenue per employee (TTM)
CHF 263,110
Management effectiveness
Return on assets (TTM)
-1.07%
Return on equity (TTM)
-1.19%
Valuation
Price to revenue (TTM)
9.921
Price to book
1.69
Price to tangible book (TTM)
4.35
Price to free cash flow (TTM)
-39.193
Free cash flow yield (TTM)
-2.55%
Free cash flow per share (TTM)
-1.48
Dividend yield (TTM)
3.32%
Forward dividend yield
3.32%
Growth
Revenue change (TTM)
-43.66%
Earnings per share change (TTM)
-110.49%
3-year revenue growth (CAGR)
-0.50%
10-year revenue growth (CAGR)
3.57%
3-year earnings per share growth (CAGR)
-16.78%
10-year earnings per share growth (CAGR)
-8.60%
3-year dividend per share growth (CAGR)
25.99%
10-year dividend per share growth (CAGR)
4.14%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.